Zacks Investment ResearchT3·1mo ago
ECOR electroCore, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ECOR
—
—
Key stats
Related
About
- Industry (SIC)
- ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS (3845) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 83
- List Date
- 2018-06-22
- CIK
- 0001560258
- Next Earnings
- 2026-11-04
- EPS Forecast
- ($0.26) (2 est.)
- Headquarters
- Rockaway, NJ
- Homepage
- https://www.electrocore.com
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 59.26% | 14.23% | 31.86% | 26.80% | -0.30% | 46.37% | 29.70% |
| Feb | -13.20% | -15.51% | -35.47% | -7.60% | -5.52% | 15.73% | -10.26% |
| Mar | -21.97% | 6.34% | 75.72% | -8.59% | -54.52% | -22.39% | -4.24% |
| Apr | -15.84% | -28.30% | 16.72% | 1.95% | 18.82% | -1.36% | -1.34% |
| May | -4.55% | 8.62% | -18.83% | 6.46% | -33.95% | 46.99% | 0.79% |
| Jun | -30.41% | -1.94% | 1.55% | 1.90% | 5.39% | -16.52% | -6.67% |
| Jul | -11.86% | 13.32% | -8.35% | -5.56% | 32.06% | -27.13% | -1.25% |
| Aug | 0.00% | -10.54% | 22.81% | -2.42% | -21.57% | 55.83% | 7.35% |
| Sep | 7.62% | -18.80% | 8.20% | 16.92% | -5.89% | 19.56% | 4.60% |
| Oct | -13.81% | -25.57% | -1.77% | 59.22% | 2.02% | -27.87%* | -1.30% |
| Nov | -25.01% | 12.27% | -9.06% | 5.81% | -0.59% | -- | -3.32% |
| Dec | -20.50% | -29.40% | 1.22% | 42.82% | -5.97% | -- | -2.37% |
| Total | -70.61% | -61.94% | 58.41% | 207.08% | -67.06% | 55.83% | 20.28% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $8.88
SMA 50: $9.69
SMA 200: $7.70
Current: $7.44
EMA 12: $8.01
EMA 26: $8.78
MACD: -0.7663 | Signal: -0.2022
BEARISH
ADX (14): 34.22
TREND
+DI: 8.31
−DI: 23.85
Momentum Oscillators
RSI (14): 31.14
NEUTRAL
Stoch %K: 7.84
Stoch %D: 5.54
Williams %R: -86.38
Volume & Volatility
BB Upper: $11.38
BB Lower: $6.37
NEUTRAL
OBV: 1,624,833
Vol SMA 20: 78,039
Vol ROC: 28.21%
ATR: $0.69
True Range: $0.52
HV 20: 51.5%
HV 30: 60.3%
HV 60: 75.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is the stock analysis report for ECOR:
Executive Summary
Overall assessment: BEARISH (Confidence level: 6/10) Key drivers: Volatility, recent price action, and mixed technical signals Primary risks: High volatility, potential earnings miss, and regulatory issues Investment thesis: The stock has been trending lower due to high volatility, which may continue if the company misses its quarterly earnings estimates. However, recent news headlines suggest a potential catalyst in the near term. Recent news sentiment impact: Positive sentiment from recent presentations and publications may offset some of the bearish momentum.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): BEARISH
- Medium-term (1-3 months): NEUTRAL
- Long-term (3-12 months): BULLISH
Support/Resistance Levels: The stock is trading below its SMA 50 and SMA 200, indicating a downtrend. Resistance lies at $9.01 (SMA 20), while support is around $6.07 (SMA 200).
Momentum Signals:
- RSI interpretation: Neutral (51.03)
- MACD signal: Bullish (0.74 / Signal: -0.16)
- Bollinger Bands position: Squeeze
Volume Analysis:
- Volume SMA 20: 183326.45
- On-Balance Volume (OBV): 2299442.07
- Volume Rate of Change: -67.07% (indicating a decline in volume)
News & Sentiment Analysis
Recent Headlines Summary: The company has recently presented at conferences and published research, generating positive sentiment.
Sentiment Assessment: Positive sentiment dominates the recent news headlines.
Catalyst Identification: Upcoming earnings reports may provide a catalyst for the stock.
Market Narrative: The positive news highlights may counterbalance some of the bearish momentum in the short term.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to market (beta >1.5).
Volatility Regime: Current volatility is high compared to historical levels.
Options Market Signals:
- IV rank: N/A
- Put/call ratios: Not available
- Unusual activity: No unusual options activity detected
Downside Protection: Support lies at $6.07 (SMA 200), which may provide some downside protection.
Market Context & Positioning
Sector Performance: The company's sector has underperformed the market in the short term.
Institutional Activity: Volume patterns suggest institutional interest is moderate to low.
Correlation Analysis: The stock moves more than the market, indicating high volatility.
Relative Valuation: The stock is trading near its 50-day moving average, which may provide some support.
Key Levels & Action Items
Critical Price Levels:
- Support: $6.07 (SMA 200)
- Resistance: $9.01 (SMA 20)
Breakout/Breakdown Levels:
- Breakout above SMA 20: Bullish signal
- Breakdown below SMA 200: Bearish signal
Time-Sensitive Catalysts:
- Upcoming earnings reports (no specific dates provided)
Risk Management:
- Stop-loss levels: Use the recent low ($7.45) as a stop-loss target.
- Position sizing considerations: Maintain a moderate position size due to high volatility.
Please note that this analysis is based on the provided data and may not reflect real-time market conditions or future events. The goal of this report is to provide an objective assessment of the stock's technical, news, and risk factors.
Generated
News
All ECOR news →
GlobeNewswire Inc.T3·2mo ago
GlobeNewswire Inc.T3·4mo ago
GlobeNewswire Inc.T3·5mo ago
GlobeNewswire Inc.T3·6mo ago
GlobeNewswire Inc.T3·6mo ago
GlobeNewswire Inc.T3·9mo ago
GlobeNewswire Inc.T3·13mo ago
GlobeNewswire Inc.T3·18mo ago
GlobeNewswire Inc.T3·18mo ago
Showing 1–10 of 50
Page 1 of 5
ECOR Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.7849
Alpha: 54.37%
Correlation: 0.2576
R-Squared: 6.6%
Stock Volatility: 88.3%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ECOR
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $378K | #4801 of 6285 | new | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $172K | #2912 of 3138 | -55.2% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $17K | #3797 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ECOR Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
ECOR Insider Trading (Form 4)
Latest: 2026-09-22Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-22 | Thomas J. Errico | Director | Buy (P) | +5,000 | $9.82 | $49.1K | EDGAR |
| 2026-09-18 | Michael Fox | See Remarks | Buy (P) | +5,000 | $9.80 | $49.0K | EDGAR |
| 2026-09-14 | Michael Fox | See Remarks | Award (A) | +5,000 | $9.80 | $49.0K | EDGAR |
| 2026-09-10 | Patricia Wilber | Director | Award (A) | +11,123 | — | EDGAR | |
| 2026-09-10 | Thomas J. Errico | Director | Award (A) | +15,572 | — | EDGAR | |
| 2026-09-10 | John P Gandolfo | Director | Award (A) | +11,123 | — | EDGAR | |
| 2026-09-10 | James Charles Theofilos | Director | Award (A) | +11,123 | — | EDGAR | |
| 2026-09-10 | Elena Bonfiglioli | Director | Award (A) | +11,123 | — | EDGAR | |
| 2026-09-10 | Michael Fox | See Remarks | Award (A) | +55,000 | — | EDGAR | |
| 2026-09-10 | Julie Ann Goldstein | Director | Award (A) | +11,123 | — | EDGAR | |
| 2026-09-10 | Joshua S. Lev | See Remarks | Award (A) | +55,000 | — | EDGAR | |
| 2026-08-25 | Joshua S. Lev | CFO and Interim President | Mixed | — | $7.25 | -$110.1K | EDGAR |
| 2026-08-17 | Thomas J. Errico | Director | Buy (P) | +5,000 | $9.85 | $49.3K | EDGAR |
| 2026-06-12 | Daniel S Goldberger | Sell (S) | −80,000 | $6.80 | -$544.0K | EDGAR | |
| 2026-05-29 | Joshua S. Lev | CFO and Interim President | Sell (S) | −6,667 | $9.00 | -$60.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ECOR Insider Holdings
10 insiders · @ $7.44
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Thomas J. Errico | Director | 369,228 | $2.75M | $743.6K | 27 | 2026-09-22 |
| 2 | Daniel S Goldberger | Chief Executive Officer | 211,471 | $1.57M | -$45.6K | 28 | 2026-06-12 |
| 3 | Joshua S. Lev | See Remarks | 139,889 | $1.04M | -$305.6K | 9 | 2026-09-10 |
| 4 | Michael Fox | See Remarks | 130,000 | $967.2K | $49.0K | 4 | 2026-09-18 |
| 5 | Julie Ann Goldstein | Director | 112,510 | $837.1K | $0 | 8 | 2026-09-10 |
| 6 | Thomas M Patton | Director | 102,782 | $764.7K | $0 | 8 | 2025-09-04 |
| 7 | John P Gandolfo | Director | 99,221 | $738.2K | $29.4K | 11 | 2026-09-10 |
| 8 | Patricia Wilber | Director | 83,448 | $620.9K | $0 | 6 | 2026-09-10 |
| 9 | Elena Bonfiglioli | Director | 41,672 | $310.0K | $0 | 2 | 2026-09-10 |
| 10 | James Charles Theofilos | Director | 34,670 | $257.9K | $0 | 2 | 2026-09-10 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ECOR Board & Officers
As of SEC filings through Sep 22, 2026Directors 7
- Thomas J. Errico · since Jun 21, 2018
- John P Gandolfo · since Apr 2, 2020
- Thomas M Patton · since Apr 2, 2020
- Julie Ann Goldstein · since Mar 15, 2022
- Patricia Wilber · since Mar 15, 2022
- James Charles Theofilos · since Aug 1, 2025
- Elena Bonfiglioli · since Sep 2, 2025
Officers 2
- Michael Fox · Co-Chief Executive Officer, President and Chief Operating Officer · listed since Sep 2026
- Joshua S. Lev · CFO and Interim President · listed since Apr 2026
Changes in the last 10 years (48)
| Sep 10, 2026 | Michael Fox listed as Co-Chief Executive Officer, President and Chief Operating Officer (previously Chief Operating Officer) in SEC filings |
| Apr 14, 2026 | Daniel S Goldberger reported in an SEC filing no longer being a director |
| Apr 14, 2026 | Daniel S Goldberger reported in an SEC filing no longer being Chief Executive Officer |
| Apr 13, 2026 | Michael Fox became Chief Operating Officer |
| Apr 1, 2026 | Joshua S. Lev listed as CFO and Interim President (previously Chief Financial Officer) in SEC filings |
| Sep 2, 2025 | Elena Bonfiglioli became a director |
| Aug 1, 2025 | James Charles Theofilos became a director |
| Feb 24, 2025 | Charles Steve Theofilos left the board, per their own SEC filing |
| Oct 4, 2024 | Joshua S. Lev became Chief Financial Officer |
| Sep 3, 2024 | The company announced the departure of Brian M Posner as Chief Financial Officer in an SEC filing |
| Jul 11, 2024 | The company announced the departure of F Peter Cuneo from the board in an SEC filing |
| Dec 8, 2023 | Charles Steve Theofilos became a director |
| Aug 4, 2023 | The company announced the departure of Trevor J Moody from the board in an SEC filing |
| May 22, 2023 | The company announced the departure of Joseph P Errico from the board in an SEC filing |
| Mar 15, 2022 | Patricia Wilber became a director |
| Mar 15, 2022 | Julie Ann Goldstein became a director |
| Mar 4, 2022 | The company announced the departure of Stephen Ondra from the board in an SEC filing |
| Mar 4, 2022 | The company announced the departure of Michael G Atieh from the board in an SEC filing |
| Jul 7, 2021 | Thomas J. Errico no longer listed as a 10% owner in SEC filings |
| Jun 15, 2021 | Joseph P Errico no longer listed as a 10% owner in SEC filings |
| Jun 16, 2020 | Thomas J. Errico first listed as a 10% owner in an SEC filing |
| Jun 16, 2020 | Joseph P Errico no longer listed as Chief Science & Strategy Officer in SEC filings |
| Apr 2, 2020 | Thomas M Patton became a director |
| Apr 2, 2020 | John P Gandolfo became a director |
| Apr 2, 2020 | F Peter Cuneo became a director |
| Nov 20, 2019 | Core Ventures II, LLC reported in an SEC filing no longer being a 10% owner |
| Oct 1, 2019 | Daniel S Goldberger became a director |
| Oct 1, 2019 | Daniel S Goldberger became Chief Executive Officer |
| Aug 20, 2019 | Thomas J. Errico no longer listed as a 10% owner in SEC filings |
| Apr 1, 2019 | Peter S. Staats reported in an SEC filing no longer being Chief Medical Officer |
| Apr 1, 2019 | Brian M Posner became Chief Financial Officer |
| Jun 21, 2018 | Trevor J Moody became a director |
| Jun 21, 2018 | Thomas J. Errico became a director |
| Jun 21, 2018 | Thomas J. Errico became a 10% owner |
| Jun 21, 2018 | Stephen Ondra became a director |
| Jun 21, 2018 | Peter S. Staats became Chief Medical Officer |
| Jun 21, 2018 | Nicholas Colucci became a director |
| Jun 21, 2018 | Michael G Atieh became a director |
| Jun 21, 2018 | Merck Global Health Innovation Fund, LLC became a 10% owner |
| Jun 21, 2018 | Joseph P Errico became a director |
| Jun 21, 2018 | Joseph P Errico became a 10% owner |
| Jun 21, 2018 | Joseph P Errico became Chief Science & Strategy Officer |
| Jun 21, 2018 | James L L Tullis became a director |
| Jun 21, 2018 | Glenn S. Vraniak became Chief Financial Officer |
| Jun 21, 2018 | Francis R. Amato became a director |
| Jun 21, 2018 | Francis R. Amato became Chief Executive Officer |
| Jun 21, 2018 | Core Ventures II, LLC became a 10% owner |
| Jun 21, 2018 | Carrie Smith Cox became a director |
Not reported recently (6)
- James L L Tullis · Last reported as a director in an SEC filing dated Apr 16, 2020
- Francis R. Amato · Last reported as a director in an SEC filing dated Jun 11, 2019
- Nicholas Colucci · Last reported as a director in an SEC filing dated Jun 11, 2019
- Carrie Smith Cox · Last reported as a director in an SEC filing dated Jun 11, 2019
- Glenn S. Vraniak · Last reported as Chief Financial Officer in an SEC filing dated Mar 26, 2019
- Merck Global Health Innovation Fund, LLC · Last reported as a 10% owner in an SEC filing dated Jun 22, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ECOR Proposed Insider Sales (Form 144)
Latest: 2026-05-27
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | PATTON THOMAS M | Director | 85,000 | $615.7K | 2026-05-22 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-05-27 | Joshua S. Lev | Interim President and Chief Financial Officer | 6,667 | $59.4K | 2026-05-27 | Shareworks by Morgan Stanley | — | EDGAR |
| 2026-05-14 | Goldberger Daniel S | Former Affiliate | 45,000 | $291.6K | 2026-05-14 | Charles Schwab & Co | — | EDGAR |
| 2026-05-05 | Goldberger Daniel S | Former Affiliate | 25,000 | $168.0K | 2026-05-05 | Charles Schwab Corp. | — | EDGAR |
| 2026-04-23 | Goldberger Daniel S | Former CEO | 10,000 | $61.3K | 2026-04-23 | Charles Schwab Corp. | — | EDGAR |
| 2025-03-25 | Theofilos Charles Steve | Director | 65,000 | $480.7K | 2025-03-25 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
4 ETFs hold ECOR
4 shown · $2.90M total exposure · 0.03% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $1.5M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $740,110 | — | 2026-09-30 |
| 3 | GWX State Street® SPDR® S&P® International Small Cap ETF | SPDR (State Street) | 0.06% | $502,394 | $896.9M | 2026-10-23 |
| 4 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.01% | $131,638 | $1.2B | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.